2024-10-01
1. Executive Summary of the Month
In September, deal-making activity saw an uptick, with 60 transactions worldwide—a 28% increase compared to August, which recorded 47 deals globally. August had a stronger focus on China’s biotech sector, representing 24 deals, while September saw 19 deals (9 out-licensing, 4 in-licensing, and 6 domestic).
The most notable out-licensing agreement in September was between Regor Therapeutics and Genentech for a portfolio of next-generation CDK Inhibitors with an upfront payment of $850 million, becoming the largest out-licensing transaction in history based on upfront payment. On the in-licensing front, ENCell and Lucy Biotech signed a deal for EN001, valued at approximately $20 million, including a $2 million upfront payment. Domestically, the standout transaction involved Alphamab Oncology and CSPC PHARMA for the oncology asset JSKN-003, with a total deal value of $427 million, including a $55 million upfront payment.
Globally, 41 licensing and collaboration agreements were announced in September. The largest of these was a partnership between Orano Med, RadioMedix, and Sanofi for 212Pb-dotamtate, valued at $346 million, with an upfront payment of $108 million.
2024年9月，全球医药市场共签署了60项资产授权和合作协议，同比8月的47项增加了28%。中国市场达成19项交易，包括9项出海交易、4项引进交易和6项国内交易，低于8月份的24项交易。
本月中国市场最引人注目的出海交易是基因泰克收购锐格医药下一代CDK抑制剂，首付8.5亿美元，成为史上最高首付款的出海交易。最值得关注的引进交易是露曦生物从ENCell 公司引进EN001，首付200万美元，总价值约2000万美元。最值得关注的国内交易是石药集团引进康宁杰瑞肿瘤资产JSKN-003，首付款5500万美元，总价值4.27亿美元。
国际市场上，9月份共签署了41项资产授权和合作协议。最大的一笔交易是是赛诺菲与Orano Med和RadioMedix就二期肿瘤资产212Pb-dotamtate达成的授权交易，首付款1.08亿美元，总价值3.46亿美元。
2. Licensing Deals
2a. Out-Licensing Deals
2b. In-Licensing Deals
2c. Domestic Licensing Deals
3. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
ACCESS CHINA
Event Name:
2024-09 药通中国秋季路演，线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM，线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco
BioToChina.org 